DOCS N Stock Overview
Designs, develops, procures, markets, sells, and distributes footwear under the Dr. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
Dr. Martens plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£29.87 |
| 52 Week High | UK£29.87 |
| 52 Week Low | UK£29.87 |
| Beta | 0.10 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -76.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| DOCS N | MX Luxury | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how DOCS N performed against the MX Luxury industry.
Return vs Market: Insufficient data to determine how DOCS N performed against the MX Market.
Price Volatility
| DOCS N volatility | |
|---|---|
| DOCS N Average Weekly Movement | n/a |
| Luxury Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: DOCS N has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine DOCS N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1945 | 2,591 | Kenny Wilson | www.drmartensplc.com |
Dr. Martens plc designs, develops, procures, markets, sells, and distributes footwear in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It offers originals, fusion, kids, and casual, as well as accessories. The company offers its products under the Dr. Martens brand name.
Dr. Martens plc Fundamentals Summary
| DOCS N fundamental statistics | |
|---|---|
| Market cap | Mex$27.91b |
| Earnings (TTM) | Mex$2.80b |
| Revenue (TTM) | Mex$21.74b |
10.0x
P/E Ratio1.3x
P/S RatioIs DOCS N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DOCS N income statement (TTM) | |
|---|---|
| Revenue | UK£1.00b |
| Cost of Revenue | UK£382.20m |
| Gross Profit | UK£618.10m |
| Other Expenses | UK£489.20m |
| Earnings | UK£128.90m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
Nov 30, 2023
| Earnings per share (EPS) | 0.13 |
| Gross Margin | 61.79% |
| Net Profit Margin | 12.89% |
| Debt/Equity Ratio | 72.6% |
How did DOCS N perform over the long term?
See historical performance and comparisonDividends
4.6%
Current Dividend Yield45%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/06/14 05:07 |
| End of Day Share Price | 2023/03/17 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2023/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Dr. Martens plc is covered by 12 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Richard Taylor | Barclays |
| David Roux | BofA Global Research |
| Louise Singlehurst | Goldman Sachs |